Objective Visual Analog Scale for Biopsy Diagnosis of Helicobacter pylori Infection in Clinical Practice

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Katherine E. Boylan ◽  
Shruti Patrey ◽  
Phillip D. McMullen ◽  
Vera Tesic ◽  
Christopher R. Weber ◽  
...  
2020 ◽  
Vol 13 ◽  
pp. 175628482096873
Author(s):  
Javier P. Gisbert

Although susceptibility-guided therapy is frequently recommended for Helicobacter pylori infection, the evidence available to date supporting this strategy is limited. The aim of the present article is to review the advantages and limitations of the susceptibility-guided and the empirical strategies to treat this infection. We performed a bibliographic search to identify studies investigating H. pylori susceptibility-guided therapy. Culture is not the only way to assess antibiotic resistance, as different polymerase chain reaction-based approaches have been developed as alternative methods. For detecting H. pylori antimicrobial resistance, a molecular approach based on a stool sample might enable more convenient, time-saving methods. Unfortunately, the antimicrobial susceptibility cannot be obtained in all cases. Furthermore, antibiotic susceptibility testing in clinical practice yields useful information only for a few antibiotics: clarithromycin, metronidazole, and quinolones. In addition, susceptibility towards clarithromycin and metronidazole in vitro does not necessarily lead to eradication in vivo. In the case of H. pylori therapy failure, we should not re-administer any of the antibiotics against which H. pylori has probably become resistant. Our updated meta-analysis showed that susceptibility-guided treatment is not better than empirical treatment of H. pylori infection in first-line therapy if the most updated quadruple regimens are empirically prescribed, and similar efficacy results were also demonstrated with the two strategies for second-line therapy. Cumulative H. pylori eradication rate with several successive rescue therapies empirically prescribed reaches almost 100%. Finally, the studies that have evaluated the cost-effectiveness of the susceptibility-guided treatment have achieved contradictory results. In summary, we can conclude that the evidence is too limited to support the generalized use of susceptibility-guided therapy for H. pylori treatment in routine clinical practice, either as first-line or as rescue treatment. Nevertheless, it would be recommended that susceptibility tests are performed routinely, even before prescribing first-line treatment, in specialized centers with an interest in H. pylori management.


2014 ◽  
Vol 56 (2) ◽  
pp. 151-156 ◽  
Author(s):  
Devapriya Appukuttan ◽  
Mythreyi Vinayagavel ◽  
Anupama Tadepalli

2018 ◽  
Vol 90 (12) ◽  
pp. 133-139 ◽  
Author(s):  
D S Bordin ◽  
I N Voynovan ◽  
S V Kolbasnikov ◽  
Yu V Embutnieks

Diagnostic tests used to detection Helicobacter pylori are divided into invasive (requiring endoscopy) and non-invasive, direct (bacteriological, histological or molecular detection of the bacterium) and indirect (detection of urease activity of the bacterium or antibodies to it). The choice of the test is determined by the clinical situation, as well as by its availability and cost. The sensitivity of most tests is affected by the use of antisecretory drugs and antibiotics.


2017 ◽  
Vol 89 (2) ◽  
pp. 84-90 ◽  
Author(s):  
D N Andreev ◽  
D T Dicheva ◽  
I V Maev

A steady decline in the effectiveness of standard eradication therapy (ET) regimens for Helicobacter pylori infection necessitates a search for ways of their optimization, by enhancing the efficiency of treatment protocols and by improving their safety and tolerability. The review systematizes the data available in the literature on main accessible methods for optimizing ET regimens. Among the optimization methods that can considerably enhance the efficiency of ET regimens, one may identify their addition of a bismuth agent (by 10—20%), the use of rebamipide (by 11.9%), adjuvant therapy with probiotics (by 8.1—13%), or double-dose proton pump inhibitors (by 8%). Only adjuvant therapy with probiotics results in a significant decrease in the incidence of side effects from ET. In posteradication period, rebamipide should be used to potentiate gastric mucosal repair and to regress inflammatory processes.


Helicobacter ◽  
2012 ◽  
Vol 17 (4) ◽  
pp. 254-263 ◽  
Author(s):  
Marco Manfredi ◽  
Barbara Bizzarri ◽  
Roberto Igino Sacchero ◽  
Sergio Maccari ◽  
Lorenzo Calabrese ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document